Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.phrs.2021.105465 http://scihub22266oqcxt.onion/10.1016/j.phrs.2021.105465 33529750!ä!33529750 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacol+Res 2021 ; 165 (ä): 105465 Nephropedia Template TP {{tp|p=33529750|t=2021. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where will the drugs come from?|pdf=|usr=}}{{33529750}} gab.com Text Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where will the drugs come from JO: Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=33529750 #FOAvip Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic debilitating disease characterized by severe and disabling fatigue that fails to improve with rest; it is commonly accompanied by multifocal pain, as well as sleep disruption, and cognitive dysfunction. Even mild exertion can exacerbate symptoms. The prevalence of ME/CFS in the U.S. is estimated to be 0.5-1.5 % and is higher among females. Viral infection is an established trigger for the onset of ME/CFS symptoms, raising the possibility of an increase in ME/CFS prevalence resulting from the ongoing COVID-19 pandemic. Current treatments are largely palliative and limited to alleviating symptoms and addressing the psychological sequelae associated with long-term disability. While ME/CFS is characterized by broad heterogeneity, common features include immune dysregulation and mitochondrial dysfunction. However, the underlying mechanistic basis of the disease remains poorly understood. Herein, we review the current understanding, diagnosis and treatment of ME/CFS and summarize past clinical studies aimed at identifying effective therapies. We describe the current status of mechanistic studies, including the identification of multiple targets for potential pharmacological intervention, and ongoing efforts towards the discovery of new medicines for ME/CFS treatment. Twit Text FOAVip Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where will the drugs come from ????Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=33529750 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33529750 #FOAvip English Wikipedia <ref>{{Cite pmid|33529750}}</ref> Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where will the drugs come from? #MMPMID33529750 Toogood PL; Clauw DJ; Phadke S; Hoffman D Pharmacol Res 2021[Mar]; 165 (ä): 105465 PMID33529750show ga Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic debilitating disease characterized by severe and disabling fatigue that fails to improve with rest; it is commonly accompanied by multifocal pain, as well as sleep disruption, and cognitive dysfunction. Even mild exertion can exacerbate symptoms. The prevalence of ME/CFS in the U.S. is estimated to be 0.5-1.5 % and is higher among females. Viral infection is an established trigger for the onset of ME/CFS symptoms, raising the possibility of an increase in ME/CFS prevalence resulting from the ongoing COVID-19 pandemic. Current treatments are largely palliative and limited to alleviating symptoms and addressing the psychological sequelae associated with long-term disability. While ME/CFS is characterized by broad heterogeneity, common features include immune dysregulation and mitochondrial dysfunction. However, the underlying mechanistic basis of the disease remains poorly understood. Herein, we review the current understanding, diagnosis and treatment of ME/CFS and summarize past clinical studies aimed at identifying effective therapies. We describe the current status of mechanistic studies, including the identification of multiple targets for potential pharmacological intervention, and ongoing efforts towards the discovery of new medicines for ME/CFS treatment. |*Drug Discovery/methods[MESH] |Analgesics/pharmacology/therapeutic use[MESH] |Animals[MESH] |Antiviral Agents/pharmacology/therapeutic use[MESH] |COVID-19/complications[MESH] |Fatigue Syndrome, Chronic/*diagnosis/*drug therapy/epidemiology/virology[MESH] |Humans[MESH]Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where wil(epmc).pdf DeepDyve Pubget Overpricing